Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Qualit-E-SpeakPharma-Insert
    X

    Find Oncology Drugs in Phase II Clinical Development in NORWAY

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              BerGenBio ASA

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              NORWAY Norway

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda® in NSCLC P...

              Contact the Supplier

              Lead Product(s): Bemcentinib,Pembrolizumab

              Therapeutic Area: Oncology

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 15, 2020

              Details:

              The clinical efficacy endpoint met for the Phase II trial cohort evaluating selective AXL inhibitor bemcentini- Keytruda combo, in patients with advanced NSCLC who failed checkpoint inhibitor therapy.

              PharmaCompass__DigitalAd